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TPQ1
THE EUROPEAN REGULATORY ISSUES
ON QUALITY OF LIFE ASSESSMENT
(ERIQA) PROJECT
Acquadro C
MAPI Research Institute, Lyon, France, for the ERIQA Group
BACKGROUND: The last 20 years have seen the develop-
ment of hundreds of health-related quality of life (HRQL)
instruments which are increasingly being used in multi-
national clinical trials. As a result, regulatory authorities
are more and more faced with HRQL as a new outcome
measure for the evaluation of new therapies. In 1997,
Mapi Research Institute organised an exploratory meet-
ing which brought together HRQL researchers and Euro-
pean regulatory representatives. The main objective was to
highlight the regulatory authorities’ concerns about HRQL
evaluation in clinical trials. Two conclusions were made:
1. There is a need to rationalise the field of HRQL re-
search and to make HRQL a credible criterion for the
evaluation of new therapies by health authorities; 2. This
issue can only be resolved through a better collaborative
effort between key players: health authorities, HRQL re-
searchers and pharmaceutical companies. Following these
conclusions, the ERIQA Project was launched.
OBJECTIVE: To provide European regulatory authorities
with guidance on how to assess the quality of HRQL stud-
ies in clinical trials, and how to evaluate the validity of
HRQL claims.
METHODS: The project is structured in 2 phases and 4
steps. Phase I will lead to the production of 3 types of doc-
uments, and presentations to regulatory authorities: 1. A
review of existing guidelines, focusing on EMEA docu-
ments; 2. A reference document, i.e., a guidance for the reg-
ulatory authorities to assess the quality of HRQL evalua-
tion and the validity of HRQL claims; 3. Pilot guidelines in
specific indications: cancer and COPD asthma. Phase II
will lead to consensus conferences with key players.
RESULTS: Preliminary results of Phase I will be pre-
sented. Collaboration with other similar US initiatives are
also planned.
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A REVIEW OF AVAILABLE HEALTH-RELATED 
QUALITY OF LIFE (HRQL) REFERENCE VALUES 
IN THE MEDICAL LITERATURE
Keininger DL, Conway K, Acquadro C, Anfray C
MAPI Research Institute, Lyon, France
BACKGROUND: Within the last 20 years, a large num-
ber of HRQL instruments have been developed and are in-
creasingly being used in multinational research and clinical
practice. However, methodological issues relating to inter-
pretation of HRQL results still need to be clarified and
there is a need for improved interpretation of HRQL re-
sults. This could be achieved through the development of
reference values. Reference values provide a means of
comparing the results of an instrument’s administration
across populations and across disease severities. The use-
fulness of reference values to interpret the burden of
chronic disease has been illustrated in numerous studies.
OBJECTIVES: The purpose of this study was to review
the available medical literature to assess the current avail-
ability of HRQL reference values.
METHODS: A thorough search of the Medline and Index
Medicus database from 1966 to the present was con-
ducted that included the following search terms: “norma-
tive data”, norms, “reference levels”, “reference values”,
“quality of life”, and “health-related quality of life”.
RESULTS: A search of the Medline and Index Medicus da-
tabases yielded eight articles that referred to the develop-
ment of reference values and 61 articles describing compar-
ative studies where comparison were made of SF-36 scores
to those of established reference values. These articles in-
cluded the development and evaluation of reference values
of the Medical Outcomes Study Short Form Health Survey
SF-36 and the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire-C30.
CONCLUSIONS: Currently, few reference values exist,
particularly, for disease specific questionnaires. Clearly,
there is a critical need for the development of reference val-
ues for different diseases and populations according to
clinical and socio-demographic criteria. These reference
values may be used to make comparisons across popula-
tions and disease severities which will provide improved
interpretation of the results of HRQL studies.
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OBJECTIVE: Many clinical trials include an HRQL as-
sessment, but very few drugs have obtained labeling or
promotional approval. This is due in part to the poor qual-
ity of HRQL assessment and reporting. The objective of
the ERIQA group is to provide European regulatory au-
thorities with guidance on how to assess the quality of
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HRQL studies in clinical trials, and how to evaluate the
validity of HRQL claims, for appropriate decision-mak-
ing.
METHOD: A guidance document and a checklist have
been designed following a literature search and using the
experience of the ERIQA group’s members, i.e., HRQL re-
searchers, pharmaceutical industry representatives, aca-
demic people, and reviewers for regulatory authorities.
RESULTS: The guidance document reviews the major is-
sues of HRQL assessment in clinical trials, and especially
practical considerations such as: selection of an HRQL
questionnaire (i.e., minimal properties required, validation
of translated versions); implementation of a HRQL assess-
ment (i.e., training of study personnel, mode of adminis-
tration, eligibility criteria, data collection, prevention of
missing data, respondent burden, multicenter trial); statis-
tical analysis (i.e., justification of the sample size, handling
of missing data, handling of multiple statistical tests), and
interpretation. For each issue, recommendations are made,
even when there is no definite answer (e.g., interpretation
of results). All the issues to be prespecified in the research
protocol are mentioned. The checklist summarizes all the
issues. It is intended to help both regulatory authority re-
viewers in performing their clinical trial reviews and spon-
sors and investigators in conducting a clinical trial with
HRQL data and writing the study report.
CONCLUSION: The final objective is to reach a large Eu-
ropean agreement upon this guidance document, to im-
prove the quality of HRQL studies and to convince Euro-
pean regulatory authorities of the usefulness and scientific
value of HRQL assessment.
TPQ4
A EUROPEAN EQ-5D VALUE SET. MYTH
OR REALITY?
De Charro F, Weijnen T, on behalf of all the participants in 
the EQ-Net Project
Institute for Medical Technology Assessment (iMTA), Erasmus 
University, Rotterdam, The Netherlands
OBJECTIVES: To harmonize VAS values resulting from 11
studies in 6 countries (England, Finland, Germany, The
Netherlands, Spain and Sweden) using the EQ-5D valuation
questionnaire, developed by the EuroQol Group. The aim is
to make available a European EQ-5D value set and to gain
insight into the influences resulting from the prevailing dif-
ferences in methodology and sample characteristics.
METHODS: The database constructed for this research
project contains data on more than 110.000 health states
from 8370 respondents. Appropriate transformation was
applied to deal with ceiling and floor effects. Regression
models and a single value decomposition were applied to
explore the differences between the valuations in the 11
samples and the influences of background variables on
the VAS values of a subset of 18 health states. Multilevel
regression analysis on data of 49 health states was con-
ducted to take into account characteristics at the individ-
ual respondent level while testing the impact of health
state characteristics on the value set.
RESULTS: In general, the impact of the background vari-
ables such as age and experience of illness on the VAS val-
uations appeared to be modest. Differences in study meth-
odology have a higher impact on the VAS values but
differences in the health states themselves were found to be
the major determinant of VAS values.
CONCLUSIONS: When corrected for the influence of the
background variables, the VAS values from the 6 countries
showed a remarkable agreement. Differences can be attrib-
uted to differences in survey methodology and sample
characteristics rather than ‘cultural’ aspects. By using a
simple instrument, ie., the EQ-5D valuation questionnaire,
it seems that an internationally consistent EQ-5D value set
can be established.
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BACKGROUND: Health-related Quality of Life (HRQL)
of patients is increasingly being used as an endpoint in
multinational studies. In this era of international collabo-
ration, there is a critical need for improved interpretation
of HRQL studies and the confirmation of conceptual
equivalence of linguistically adapted HRQL instruments
used in multinational studies. In order to facilitate these
two objectives, Mapi Research Institute has launched the
development of IQOD.
OBJECTIVES: The primary objective of the IQOD proj-
ect is the development of an international database that
will contain HRQL, socio-demographic, and clinical data
from multinational HRQL studies. Once this database is
developed the following objectives can be realised: (1)
Development of reference values to facilitate interpreta-
tion of scale scores and making it possible to estimate the
relative burden of various medical and psychological con-
ditions across populations and across disease severities;
(2) Evaluation of the conceptual equivalence of linguisti-
cally adapted HRQL instruments used in multinational
studies; (3) Development of item banking.
METHODS: During the initial phase of this project, data
will be obtained from sponsors of international studies in
which linguistically valid HRQL questionnaires, provided
by Mapi Research Institute, were administered. There are
13 instruments included in the initial phase of this project.
The first step of the initial phase is the development of ref-
erence values for the Women’s Health Questionnaire
(WHQ) and the Minnesota Living with Heart Failure
Questionnaire (MLHF).
RESULTS: Results of the initial phase will be presented
upon completion of analysis.
